207 related articles for article (PubMed ID: 23285063)
41. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
42. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
Front Immunol; 2018; 9():2060. PubMed ID: 30271406
[TBL] [Abstract][Full Text] [Related]
43. Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide.
Zykova AA; Blokhina EA; Kotlyarov RY; Stepanova LA; Tsybalova LM; Kuprianov VV; Ravin NV
Viruses; 2020 Oct; 12(10):. PubMed ID: 33036278
[TBL] [Abstract][Full Text] [Related]
44. Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation.
Wang W; Huang B; Jiang T; Wang X; Qi X; Tan W; Ruan L
Virology; 2014 Nov; 468-470():265-273. PubMed ID: 25213406
[TBL] [Abstract][Full Text] [Related]
45. Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
Kolpe A; Schepens B; Ye L; Staeheli P; Saelens X
Antiviral Res; 2018 Oct; 158():244-254. PubMed ID: 30179634
[TBL] [Abstract][Full Text] [Related]
46. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.
Vignuzzi M; Gerbaud S; van der Werf S; Escriou N
J Gen Virol; 2001 Jul; 82(Pt 7):1737-1747. PubMed ID: 11413386
[TBL] [Abstract][Full Text] [Related]
47. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
[TBL] [Abstract][Full Text] [Related]
48. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
49. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
[TBL] [Abstract][Full Text] [Related]
50. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
[TBL] [Abstract][Full Text] [Related]
51. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
[TBL] [Abstract][Full Text] [Related]
52. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
[TBL] [Abstract][Full Text] [Related]
53. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes.
Stepanova LA; Mardanova ES; Shuklina MA; Blokhina EA; Kotlyarov RY; Potapchuk MV; Kovaleva AA; Vidyaeva IG; Korotkov AV; Eletskaya EI; Ravin NV; Tsybalova LM
J Biomed Sci; 2018 Apr; 25(1):33. PubMed ID: 29631629
[TBL] [Abstract][Full Text] [Related]
54. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.
Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonosoff GP; Ravin NV
BMC Biotechnol; 2015 May; 15():42. PubMed ID: 26022390
[TBL] [Abstract][Full Text] [Related]
55. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
[TBL] [Abstract][Full Text] [Related]
56. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.
Wang L; Hess A; Chang TZ; Wang YC; Champion JA; Compans RW; Wang BZ
Nanomedicine; 2014 Feb; 10(2):473-82. PubMed ID: 23988715
[TBL] [Abstract][Full Text] [Related]
57. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF
Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830
[TBL] [Abstract][Full Text] [Related]
58. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein.
Andersson AM; Håkansson KO; Jensen BA; Christensen D; Andersen P; Thomsen AR; Christensen JP
PLoS One; 2012; 7(10):e46395. PubMed ID: 23049700
[TBL] [Abstract][Full Text] [Related]
59. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
Kim MH; Kang JO; Kim JY; Jung HE; Lee HK; Chang J
Antiviral Res; 2019 Mar; 163():19-28. PubMed ID: 30639307
[TBL] [Abstract][Full Text] [Related]
60. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype.
Ameiss K; Ashraf S; Kong W; Pekosz A; Wu WH; Milich D; Billaud JN; Curtiss R
Vaccine; 2010 Sep; 28(41):6704-13. PubMed ID: 20691653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
